Samsung BioLogics Fined for Exaggerating Its Value
06 December, 2018
The Financial Services Commission on Wednesday fined Samsung BioLogics W8 billion for intentionally inflating its value ahead of its public offering in 2016 (US$1=W1,114).
Last month, the watchdog's committee recommended the fine and reported the company's CEO and other top officials to police.
Samsung BioLogics has filed an administrative lawsuit seeking to void the penalty, which cannot be collected as long as the case is being reviewed by a court.
TAG(s):